Bionano Genomics (BNGO) Accumulated Expenses (2017 - 2026)

Bionano Genomics has reported Accumulated Expenses for 10 years, with the latest figure at $4.0 million in Q1 2026.

• Quarterly Accumulated Expenses rose 1.5% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 1.5% YoY) and the FY2025 annual result came in at $3.5 million, down 37.3% from the prior year.
• Accumulated Expenses advanced to $4.0 million in Q1 2026 per BNGO's latest filing, from $3.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $11.7 million in Q3 2022 and troughed at $3.4 million in Q2 2025.
• A 5-year average of $7.3 million and a median of $7.8 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses surged 91.8% in 2022, then sank 64.3% in 2025.
• Over 5 years, Accumulated Expenses stood at $10.6 million in 2022, then declined by 23.34% to $8.1 million in 2023, then tumbled by 30.26% to $5.6 million in 2024, then plunged by 37.3% to $3.5 million in 2025, then gained by 12.98% to $4.0 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $4.0 million, $3.5 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.